Nursing notes: High-Risk Pregnancy, Diabetes, Hypertension, and Substance Use
High-Risk Pregnancy: Definition and Scope
High-risk pregnancy definition: a pregnancy in which the life or health of the mother, fetus, or both is jeopardized by a disorder or a condition that is coincidental with or unique to pregnancy.
Conditions that can cause a pregnancy to be at risk include:
Hypertension (chronic or gestational)
Diabetes mellitus (type 1, type 2, or gestational)
Cardiac disease
Renal disorders
Autoimmune diseases
Thyroid disorders
Obesity or underweight
Mental health disorders (depression, anxiety)
Substance use
Pregnancy-related complications to monitor for:
Hyperemesis gravidarum
Hemorrhagic events: placenta previa, placental abruption
Infections: TORCH infections, UTIs, HIV
Multiple gestation
Preterm labor and premature rupture of membranes (PROM)
Fetal growth restriction (FGR)
Isoimmunization
Preeclampsia and eclampsia
Amniotic fluid abnormalities: oligohydramnios, polyhydramnios
Demographic risk factors:
Maternal age <17 or >35
Lack of prenatal care
Low socioeconomic status
Intimate partner violence
Teenage pregnancy
Nursing role in high-risk pregnancy:
Assessment: frequent, comprehensive assessments; monitor vital signs and weight; fetal heart rate monitoring (intermittent or continuous); fundal height; fetal movement; lab monitoring (CBC, urine protein, glucose); monitor for signs of complications (headache, blurred vision, bleeding, decreased fetal movement).
Planning and prioritization: identify actual and potential complications; collaborate with interdisciplinary team (OB, MFM, endocrinology, dietitian, social worker); educate and involve patient and family in plan of care.
Diabetes in Pregnancy
Classifications:
Pregestational diabetes: type 1 or type 2 existing before pregnancy
Gestational diabetes mellitus (GDM): glucose intolerance first recognized during pregnancy
Screening:
All with pregestational diabetes: screen at first prenatal visit
GDM screening routinely between 24 and 28 weeks gestation
Early screening before 24 weeks if high risk (to detect undiagnosed type 2 diabetes)
Why screen:
Detect undiagnosed type 2 diabetes early
Identify gestational diabetes (usually develops in second half of pregnancy due to increasing insulin resistance)
Initiate early management to prevent maternal and fetal complications
Early screening risk factors for early testing:
BMI ≥ 25
History of GDM or prior macrosomic infant (≥ 4000 g)
First-degree relative with diabetes
Hypertension, PCOS, history of unexplained stillbirths
Known impaired glucose tolerance or fasting glucose
High-risk race/ethnicity (e.g., African American, Latino, Native American, South/East Asian, or Pacific Islander)
Pathophysiology of diabetes in pregnancy:
Not a single disease but a metabolic state influenced by placental hormones, maternal insulin sensitivity, and β-cell reserve
Two main categories: pregestational diabetes and gestational diabetes
Normal metabolic changes in pregnancy:
Two phases: anabolic (early pregnancy) and catabolic (late pregnancy)
Hormones: increased estrogen and progesterone -> increased insulin sensitivity and β-cell hyperplasia -> increased insulin secretion
Metabolic effects: increased glycogen storage in liver/muscle; increased lipogenesis; decreased fasting glucose due to uptake by maternal tissues and fetus
Clinical correlation:
Women with preexisting type 1 diabetes may require lower insulin doses in the anabolic phase (risk of hypoglycemia)
Diabetes in pregnancy: catabolic phase (late pregnancy, >20 weeks):
Hormones rising: human placental lactogen (HPL), progesterone, estrogen, cortisol, placental growth hormone
Anti-insulin effects -> insulin resistance increases
Metabolic effects: ↑ lipolysis (↑ FFAs); ↑ hepatic gluconeogenesis (more glucose to fetus); ↓ maternal glucose uptake by muscle/fat
Insulin requirements rise progressively (often 2–4x baseline) in type 1
Hormonal contributions:
HPL: placental insulin antagonist -> ↑ lipolysis; ↓ maternal glucose uptake
Progesterone: ↑ insulin resistance; modulates β-cell function
Estrogen: promotes lipogenesis and insulin resistance
Cortisol: ↑ hepatic gluconeogenesis; ↓ glucose uptake
Placental growth hormone: promotes insulin resistance
Pathophysiology summary: progressive, hormone-driven insulin resistance; hepatic glucose output ↑; peripheral glucose utilization ↓; β-cell compensation may fail
Maternal and fetal consequences of diabetes in pregnancy:
Maternal: hyperglycemia -> osmotic diuresis, dehydration, electrolyte loss; lipolysis -> ketosis; risk of DKA; vascular complications (retinopathy, nephropathy, CV disease risk)
Obstetric complications: preeclampsia, polyhydramnios, preterm labor
Fetal/neonatal: maternal hyperglycemia -> fetal hyperglycemia -> fetal hyperinsulinemia -> macrosomia (> 4000 g); shoulder dystocia; organomegaly (liver, heart); neonatal hypoglycemia; RDS due to impaired surfactant; polycythemia; hyperbilirubinemia; chronic intrauterine hypoxia -> polycythemia; risk of stillbirth with poor glycemic control late in pregnancy
Timeline of insulin needs in diabetic pregnancy:
1st trimester: decreased insulin need (↑ insulin sensitivity; high fetal glucose uptake)
2nd trimester: gradual increase in insulin need (rising placental hormones)
Late 3rd trimester: sharp increase (2–4× baseline) due to peak insulin resistance
Immediate postpartum: drastic fall in insulin needs (loss of placental hormones; rapid normalization)
Nursing implications for diabetes in pregnancy:
Screening and glycemic targets; educate on glucose monitoring, diet, exercise, medication adherence
Fetal monitoring: growth scans and nonstress tests (NSTs) or biophysical profiles (BPP)
Labor management: maintain maternal glucose between 70–110 mg/dL; IV insulin may be needed; continuous fetal monitoring
Postpartum follow-up: 6–12 weeks OGTT to assess persistent diabetes; lifelong monitoring for gestational diabetes patient (risk of type 2 later in life)
Glycemic targets in pregnancy:
Fasting:
1 hour postprandial:
2 hour postprandial:
Bedtime/pre-meal:
Assessment framework for diabetes in pregnancy:
Subjective data: prepregnancy diagnosis, prior pregnancies, family history, upstitcher history, prior GDM/macrosomia, polyhydramnios, current pregnancy symptoms (polyuria, polydipsia, fatigue, vision changes, fetal movement changes)
Objective data: vital signs, BP, weight; labs (fasting glucose, 1h/2h postprandial, HbA1c); urinalysis for glucose/ketones/protein; renal function (BUN, creatinine); 24h urine protein if indicated; electrolytes if concerned about DKA
Physical assessment: appearance (fatigued/dehydrated), skin (poor healing), abdominal findings (fundal height, fetal growth), fetal movements, fetal heart tones, edema, reflexes (hyperreflexia may signal preeclampsia), vascular signs; fetal assessment (ultrasound in 2nd/3rd trimester for growth, amniotic fluid volume, anatomy; BPP; NST; kick counts; Doppler for placental insufficiency)
Monitoring schedule and red flags:
Prenatal visits: weight, BP, urine dip for glucose/protein/ketones; insulin adjustments if needed; review glucose logs
28–32 weeks: kick counts and growth ultrasound
32–36 weeks: NST or BPP
36 weeks+: weekly or biweekly NSTs; delivery planning; fetal surveillance for macrosomia, amniotic fluid volume, IUGR; Doppler studies if indicated
Postpartum: OGTT at 6–12 weeks; continue screening every 1–3 years for type 2 risk
Red flags: persistent hyperglycemia or ketonuria; reduced fetal movement; preeclampsia signs (headache, visual changes, RUQ pain, BP elevation, proteinuria); signs of DKA; preterm labor symptoms
Goals of treatment:
Maintain maternal euglycemia
Prevent maternal complications (preeclampsia, DKA, infection)
Prevent fetal/neonatal complications (macrosomia, hypoglycemia, stillbirth)
Support fetal growth and safe labor/delivery
Treatment components:
Medical Nutrition Therapy (MNT): individualized meal plan by a registered dietitian; goal to stabilize glucose and appropriate weight gain
General recommendations: three small meals + 2–3 snacks daily; complex carbohydrates 40–50%; protein 20–25%; fats 30–40%
Avoid simple sugars and refined carbs; emphasize low glycemic index foods; include bedtime snack to prevent ketosis
Physical activity: moderate activity (e.g., walking, swimming, prenatal yoga) 30 minutes/day, 5–7 days/week; improves insulin sensitivity and lowers postprandial glucose
Glucose monitoring targets (as above)
Pharmacotherapy:
First-line: insulin (preferred; does not cross placenta)
Rapid-acting insulins: Lispro or Aspart for postprandial spikes
Intermediate-acting: NPH for basal control
Long-acting: Detemir (used in pregestational diabetes)
Dosing: adjusted frequently due to changing insulin resistance
Oral hypoglycemics: second-line/adjunct (not FDA-approved for pregnancy but used off-label when insulin is refused or not feasible)
Metformin: crosses placenta; minimal adverse fetal outcomes
Glyburide (glibenclamide): older option; higher risk of neonatal hypoglycemia
Fetal surveillance during treatment: kick counts and growth ultrasounds every 4–6 weeks; NSTs and BPP in late pregnancy, especially if on medications; monitor amniotic fluid index
Intrapartum management: monitor glucose every 1–2 hours during labor; maintain maternal glucose between 70–110 mg/dL; IV insulin or dextrose drip as needed; vaginal delivery preferred unless obstetric indication for cesarean
Postpartum management: most women return to normal glucose tolerance within 24–72 hours; discontinue insulin postpartum unless hyperglycemia persists; continue glucose screening and postpartum follow-up; lifelong lifestyle counseling
Gestational Diabetes Mellitus (GDM): pathophysiology and differences from pregestational diabetes
GDM is glucose intolerance first recognized during pregnancy, developing in mid-to-late pregnancy when insulin resistance is highest
Usually resolves after delivery but increases lifetime risk of type 2 diabetes (35–60% risk within 10–20 years)
Pathophysiology recap: placental hormones (HPL, progesterone, estrogen, cortisol, placental growth hormone) cause progressive insulin resistance; β-cell compensation may be insufficient -> hyperglycemia -> placental glucose transfer -> fetal hyperinsulinemia -> macrosomia
Fetal/neonatal consequences include macrosomia, shoulder dystocia, neonatal hypoglycemia, RDS, polycythemia, hyperbilirubinemia, hypocalcemia, hypomagnesemia; long-term risks include obesity and impaired glucose tolerance
Screening/timing: same targets as above; risk-based early screening as noted
Diagnostic and management focus:
MNT and physical activity as first-line therapy
Glucose monitoring targets identical to those for pregnancy with diabetes
Pharmacologic therapy if needed (insulin preferred; oral agents used off-label in some cases)
Fetal surveillance (kick counts, growth ultrasounds; NST/BPP; Doppler studies as indicated)
Intrapartum management similar to pregestational diabetes when insulin-dependent or poorly controlled
Delivery planning: timing guided by maternal glycemic control and fetal status; often delivery near term if well-controlled
Postpartum: GDM typically resolves; assess with 75 g OGTT at 6–12 weeks; ongoing risk for type 2 diabetes with long-term follow-up and lifestyle counseling
Chronic Hypertension in Pregnancy
Definition: hypertension present before pregnancy or diagnosed before 20 weeks or persisting beyond 12 weeks postpartum
Diagnostic criteria: systolic ≥
SBP ≥ 140 mmHg or DBP ≥ 90 mmHg on at least two occasions ≥ 4 hours apart
Pathophysiology: increased peripheral vascular resistance and/or increased cardiac output due to chronic vascular remodeling
Pregnancy impact: normal pregnancy causes vasodilation and BP drop in 1st trimester; chronic HTN blunts this, risking placental insufficiency
Cellular/vascular changes: endothelial dysfunction, arterial stiffness, chronic inflammation
Risk of superimposed preeclampsia
Risk factors: maternal age > 35, pre-pregnancy BMI > 30, African American, family history of hypertension, prior preeclampsia, diabetes, CKD, connective tissue disorders, thyroid disorders, high-sodium diet, sedentary lifestyle, smoking
Maternal complications: superimposed preeclampsia, placental abruption, preterm labor, stroke, chronic kidney disease progression, cardiomyopathy
Fetal/neonatal complications: FGR, oligohydramnios, preterm birth, stillbirth
Management:
Preconception: optimize BP, switch to pregnancy-safe antihypertensives (labetalol, nifedipine, methyldopa); avoid ACE inhibitors, ARBs, direct renin inhibitors; lifestyle modifications
Antenatal: treat severe BP (≥ 160/110) promptly; target BP roughly 120–160 systolic and 80–105 diastolic; low-dose aspirin 81 mg daily from 12–16 weeks to reduce preeclampsia risk
Fetal surveillance: growth ultrasounds every 4 weeks from 28–32 weeks; NST/BPP 32–34 weeks; hospitalize for severe hypertension or fetal compromise
Intrapartum: continue antihypertensives; avoid maternal hypotension; vaginal delivery preferred unless obstetric indication for cesarean
Postpartum: BP normalization by ~12 weeks postpartum; monitor for persistent hypertension and long-term cardiovascular risk; adjust antihypertensives for breastfeeding safety (labetalol, nifedipine, methyldopa are compatible with lactation)
Key nursing points: accurate BP measurement; assess for preeclampsia signs; promote home BP monitoring; advise on low-sodium diet and hydration; encourage moderate activity unless contraindicated
Gestational Hypertension
Definition: new-onset hypertension after 20 weeks without proteinuria or signs of end-organ dysfunction
Diagnostic criteria: SBP ≥ 140 mmHg or DBP ≥ 90 mmHg on two occasions at least 4 hours apart after 20 weeks gestation
Typically resolves within 12 weeks postpartum
If proteinuria or systemic involvement develops, progression to preeclampsia
Pathophysiology: abnormal placental vascular remodeling and maternal vascular dysfunction; placenta may release anti-angiogenic factors -> systemic vasoconstriction
Diagnostic criteria for proteinuria if present: ≥ 300 mg/24 h or protein/creatinine ratio ≥ 0.3 or dipstick ≥ 1+
If thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema, or neurologic symptoms develop, diagnosis may shift toward preeclampsia
Risk factors: first pregnancy, maternal age < 20 or > 40, multifetal gestation, obesity (BMI > 30), family history of preeclampsia, prior GH, metabolic syndrome/insulin resistance
Maternal complications: progression to preeclampsia or eclampsia, placental abruption, HELLP, stroke, CV events
Fetal complications: FGR, oligohydramnios, preterm birth, fetal demise
Management:
Outpatient: home BP monitoring; weekly to biweekly prenatal visits; serial urine tests; fetal surveillance (NST, BPP, growth ultrasounds every 3–4 weeks)
Inpatient: for severe hypertension or fetal compromise
Antihypertensive therapy as indicated; delivery timing individualized by maternal/fetal status
Preeclampsia and Eclampsia
Preeclampsia definition: new-onset hypertension after 20 weeks with proteinuria or signs of end-organ dysfunction in the absence of another explanation
Diagnostic criteria: BP ≥ 140/90 on two occasions ≥ 4 hours apart after 20 weeks; proteinuria ≥ 300 mg/24h or protein/creatinine ratio ≥ 0.3 or dipstick ≥ 1+; without proteinuria, presence of thrombocytopenia, renal impairment, hepatic dysfunction, pulmonary edema, or new CNS/visual disturbances
Pathophysiology: abnormal placentation -> shallow trophoblastic invasion -> narrow/high-resistance spiral arteries -> placental ischemia -> angiogenic/inflammatory mediator release -> systemic endothelial dysfunction -> edema, vasoconstriction, multi-organ involvement
Maternal complications: eclampsia, HELLP, stroke, DIC, placental abruption, liver hematoma/rupture, renal failure
Fetal complications: FGR, oligohydramnios, preterm birth, intrauterine fetal demise, placental insufficiency
Management by features:
Preeclampsia without severe features: aim to prolong pregnancy to allow fetal maturation with close monitoring; frequent BP and urine protein checks; fetal surveillance (NST, ultrasound); plan delivery at ≥ 37 weeks if stable
Preeclampsia with severe features: hospitalization; antihypertensives (labetalol, hydralazine, or nifedipine); magnesium sulfate for seizure prophylaxis; administer corticosteroids if < 34 weeks for fetal lung maturity; delivery at 34 weeks or sooner if unstable
Intrapartum: continuous fetal monitoring; maintain BP < 160/110; continue magnesium sulfate during labor and for 24 hours postpartum
Postpartum: BP may remain elevated for days to weeks; monitor for late eclampsia up to 6 weeks postpartum; counseling on long-term cardiovascular risk
HELLP syndrome (a severe form/complication of preeclampsia or eclampsia)
Definition: Hemolysis, Elevated Liver enzymes, Low Platelets
Occurs in ~10–20% of women with severe preeclampsia
Pathophysiology: endothelial dysfunction with microvascular injury -> hepatic ischemia/necrosis -> elevated AST/ALT; coagulation cascade activation -> thrombocytopenia; schistocytes and hemolysis -> low haptoglobin, elevated LDH, indirect bilirubin
Clinical features: malaise, nausea/vomiting, RUQ or epigastric pain; hypertension may be present or not
Diagnosis labs: elevated LDH; fragmented RBCs on smear; low haptoglobin; elevated AST/ALT; platelets < 100,000/mm³; other labs: uric acid, bilirubin, prolonged coagulation times
Maternal complications: DIC, hepatic hematoma/rupture, acute renal failure, pulmonary edema, placental abruption, stroke, death
Fetal complications: prematurity, IUGR, stillbirth
Management: immediate hospitalization and stabilization; delivery is definitive treatment; BP control; MgSO₄; transfusion if platelets very low or bleeding risk; monitor liver/renal function and coagulation; fetal status with continuous monitoring
Nursing considerations: monitor for worsening liver injury/bleeding; assess neurologic status; prepare for potential emergency cesarean; patient and family education; supportive care
Iron-Deficiency Anemia in Pregnancy
Cause/risk: insufficient iron intake; pregnancy increases iron needs due to expanded maternal blood volume and fetal demands; other risks include blood loss, vegetarian diet, GI malabsorption, heavy menses, GI bleeding, bariatric surgery, Crohn’s disease, etc.
Role of iron: essential for hemoglobin synthesis; deficiency leads to microcytic, hypochromic RBCs and reduced oxygen delivery
Clinical manifestations: fatigue, pallor, dyspnea on exertion, dizziness, pica, glossitis, angular cheilitis, brittle nails, tachycardia
Lab findings: CBC with low Hb/Hct and microcytic, hypochromic indices; iron studies show low ferritin, low serum iron, high TIBC, low transferrin saturation
Diagnosis: CBC and iron studies; stool occult blood or endoscopy if indicated
Treatment:
Address underlying cause
Iron supplementation (oral ferrous sulfate) with vitamin C; avoid calcium with iron supplements
Dietary counseling and iron-rich foods
Nursing considerations:
Ensure compliance and manage GI side effects (constipation, dark stools, GI upset)
Monitor Hb and ferritin levels during treatment; assess ongoing blood loss in pregnancy
For pregnant women: ensure prenatal vitamins contain adequate iron
Complications if untreated: heart failure; impaired fetal cognitive/physical development; preterm birth; low birth weight; increased maternal/fetal risks
Vulnerable Populations in Pregnancy
Pregnant adolescents
Nursing assessment: build rapport; nonjudgmental approach; ensure privacy; age-appropriate language
Health history focus: gestational age, prenatal care history, STIs, contraception use, medical/surgical history, immunizations, menstrual history, psychosocial factors, social support and living situation
Psychosocial: screen for depression, anxiety, abuse; assess coping, readiness for behavioral changes; assess knowledge about prenatal and newborn care
Physical examination: vital signs; pallor; thyroid; breast development; abdominal exam; fundal height; fetal heart tones; fetal position; edema; varicosities; reflexes; signs of vascular compromise
Labs: urine dipstick (protein, glucose, ketones); CBC with Hb/Hct; blood type and Rh; STI screening; gestational diabetes screening; iron, folate, vitamin D as indicated
Interventions: tailored education on prenatal care, nutrition, and lifestyle; facilitate access to support services; counseling, WIC; monitor for depression/abuse; encourage continued schooling if possible; promote regular prenatal visits
Pregnant women aged >35 (Advanced Maternal Age, AMA)
AMA pregnancy: enhanced surveillance and individualized care
Risk factors: chromosomal abnormalities, pregnancy complications, adverse outcomes
Comprehensive health assessment: obstetric/gynecologic history; prior pregnancy outcomes; preexisting conditions (HTN, diabetes, thyroid disease); family history of genetic disorders; lifestyle factors (smoking, alcohol, drugs); medications/supplements
Physical assessment: baseline vitals, weight/BMI, cardiac/respiratory/abdominal exam; fundal height and fetal heart tones
Laboratory/diagnostic tests: early prenatal genetic screening; glucose tolerance test for GDM; CBC, thyroid function, infectious disease screening; ultrasound for fetal anatomy and growth; regular fetal well-being assessments
Education/support: genetic testing options; informed decision-making; monitor for GDM and HTN/preeclampsia; watch for preterm labor, placenta previa/abruption; risk of miscarriage or stillbirth; possibility of cesarean delivery; discuss lifestyle modifications (folic acid, iron, calcium; physical activity; smoking cessation; alcohol avoidance)
Postpartum planning: breastfeeding support; contraception counseling
Psychosocial: assess stress, anxiety, depression; ensure support networks and involvement in childbirth education for AMA
Substance use during pregnancy
Substances and effects:
Alcohol: maternal nutritional deficiencies and hypertension; fetal alcohol spectrum disorders (FASD); growth restriction and neurodevelopmental delays
Tobacco: placental abruption, preterm labor; fetal effects include low birth weight, IUGR, SIDS risk
Cocaine: vasoconstriction and placental abruption; preterm birth, growth restriction, CNS abnormalities
Opioids: infection risk, overdose; neonatal abstinence syndrome (NAS); preterm birth
Marijuana: possible impaired fetal growth; potential cognitive/behavioral issues
Methamphetamine: maternal hypertension/preeclampsia risk; fetal growth restriction, preterm birth, neurodevelopmental delays
Nursing assessment and management:
Obtain nonjudgmental, thorough substance use history; screen with validated tools
Assess prenatal care adequacy and nutritional status; monitor withdrawal or intoxication signs
Evaluate mental health status and coexisting psychiatric disorders; assess social support and living environment
Plan for safe detoxification with addiction specialists if indicated; coordinate with social work and obstetric team
Develop plan for pain management in labor (avoid opioids if possible for opioid users); plan for neonatal withdrawal after birth
Postpartum: monitor for NAS in newborns; promote continuity of prenatal care; referrals to addiction treatment and support groups; contraception counseling; screen for postpartum depression
Legal/ethical: understand local laws; advocate while maintaining confidentiality; prepare for mandatory reporting if applicable
Fetal Alcohol Spectrum Disorders (FASD)
Fetal Alcohol Syndrome (FAS) is the most severe form of FASD
Causes physical, cognitive, and behavioral abnormalities due to prenatal alcohol exposure
Alcohol crosses placenta and disrupts cell proliferation, migration, and differentiation during organogenesis
Features and risk factors:
Facial features: smooth philtrum, thin vermilion border, small palpebral fissures
Midface hypoplasia; small jaw; growth deficiency; CNS abnormalities
CNS: microcephaly, abnormal brain morphology, cognitive and behavioral deficits; learning difficulties, attention deficits, hyperactivity
Risk factors: amount, frequency, and timing of alcohol intake (especially 1st trimester); genetic susceptibility; poor maternal nutrition; lack of prenatal care
Complications: lifelong cognitive/behavioral problems, school difficulties, social adaptation issues, increased risk of mental health disorders, potential seizures
Diagnosis: clinical criteria combining confirmed prenatal alcohol exposure, facial features, growth deficits, and CNS dysfunction
Management: multidisciplinary approach (special education, therapy, mental health support, family counseling, social support)
Prevention: avoid alcohol entirely during pregnancy; public health education; screening and counseling for women of childbearing age; early diagnosis and intervention when needed
Key takeaways
Gestational diabetes develops after organogenesis and usually does not cause congenital malformations; placental hormones drive insulin resistance
Major fetal complications include macrosomia and neonatal hypoglycemia; lifelong type 2 diabetes risk for mother and child exists after GDM
Blood glucose targets in pregnancy are stricter than in nonpregnant adults; delivery planning depends on maternal/fetal status
Chronic hypertension and gestational hypertension carry risks for preeclampsia, placental pathologies, and fetal complications; aspirin prophylaxis reduces preeclampsia risk
Preeclampsia requires delivery as the only definitive cure when severe
HELLP is a severe complication of preeclampsia/eclampsia requiring urgent management
Iron-deficiency anemia in pregnancy demands iron supplementation and dietary changes to prevent maternal and fetal adverse outcomes
Adolescent and AMA pregnancies require tailored assessment, education, and enhanced surveillance
Substance use during pregnancy poses significant maternal and fetal risks; a nonjudgmental, multidisciplinary approach improves engagement and outcomes
FASD represents lifelong implications; prevention through abstaining from alcohol during pregnancy is essential